The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA).
Hans-Joachim Schmoll
Consultant or Advisory Role - Merck; Roche
Research Funding - Merck; Roche
Josep Tabernero
Consultant or Advisory Role - Roche; Sanofi
Jean Alfred Maroun
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Filippo G. De Braud
Consultant or Advisory Role - Sanofi
Honoraria - Roche; Sanofi
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Eric Van Cutsem
Research Funding - Roche
Mark Hill
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Silke Hoersch
Employment or Leadership Position - Dr. Manfred Koehler GmbH/Roche
Karen Rittweger
Employment or Leadership Position - Roche
David Chen
Employment or Leadership Position - Roche
Daniel G. Haller
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche